Roivant Sciences Ltd. (NASDAQ: ROIV) stock fell -1.74% on Friday to $11.29 against a previous-day closing price of $11.49. With 22.38 million shares changed hands, the volume of the stock remained heavier than its average volume of 5.12 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.56 whereas the lowest price it dropped to was $11.22. The 52-week range on ROIV shows that it touched its highest point at $12.84 and its lowest point at $2.87 during that stretch. It currently has a 1-year price target of $15.62. Beta for the stock currently stands at 1.28.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ROIV was down-trending over the past week, with a drop of -10.40%, but this was up by 4.44% over a month. Three-month performance surged to 13.81% while six-month performance rose 32.82%. The stock gained 206.79% in the past year, while it has gained 41.30% so far this year. A look at the trailing 12-month EPS for ROIV yields -1.48 with Next year EPS estimates of -1.18. For the next quarter, that number is -0.29. This implies an EPS growth rate of -24.90% for this year and 2.50% for next year.
Float and Shares Shorts:
At present, 759.27 million ROIV shares are outstanding with a float of 512.76 million shares on hand for trading. On Aug 30, 2023, short shares totaled 21.19 million, which was 2.75% higher than short shares on Jul 30, 2023. In addition to Mr. Matthew Gline as the firm’s CEO & Director, Dr. Eric Venker M.D., Pharm.D. serves as its Pres & COO.
Institutional Ownership:
Through their ownership of 58.52% of ROIV’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.93% of ROIV, in contrast to 56.50% held by mutual funds. Shares owned by individuals account for 41.79%. As the largest shareholder in ROIV with 15.86% of the stake, QVT Financial LP holds 122,431,775 shares worth 122,431,775. A second-largest stockholder of ROIV, Viking Global Investors LP, holds 75,238,700 shares, controlling over 9.75% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in ROIV, holding 35,969,472 shares or 4.66% stake.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, ROIV reported revenue of $4.32M and operating income of -$282.31M. The EBITDA in the recently reported quarter was -$322.63M and diluted EPS was -$0.48.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ROIV since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ROIV analysts setting a high price target of $23.00 and a low target of $12.00, the average target price over the next 12 months is $15.88. Based on these targets, ROIV could surge 103.72% to reach the target high and rise by 6.29% to reach the target low. Reaching the average price target will result in a growth of 40.66% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
